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At present, the only recognised prognostic factor for primary osteosarcoma is the histological response to preoperative
chemotherapy. Our study was designed to identify new diagnostic markers that could eventually have a prognostic value. A total of
54 patients under 20 years of age with primary osteosarcomas were studied while under treatment by the French Society of
Paediatric Oncology OS 94 protocol. Paired normal and biopsy samples were collected. In addition, surgical resection specimens,
following preoperative chemotherapy, were obtained in 13 cases. After genomic DNA extraction, an allelotyping analysis targeting
microsatellites linked to Rb and p53 genes, and 9p21, 7q31 and 5q21 regions was performed. In all, 94% of the samples at diagnosis
showed allelic imbalance and the biopsies were highly rearranged except for the microsatellite targeting 7q31. The same panel was
highly informative at surgical resection. Microsatellites investigating Rb, p53 and the 9p21 region were particularly altered without a
significant correlation with prognosis. On the other hand, the alteration of the 7q31 locus at diagnosis was significantly correlated with
a worse prognosis and a new frequently altered locus, 5q21, was described. In conclusion, this panel allowed us to characterise
paediatric osteosarcomas. Correlation of prognosis with the altered 7q31 region could be a useful tool and further studies are
required to confirm the importance of 5q21.
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Primary high-grade osteosarcoma is the most frequent malignant
bone cancer in childhood accounting for about 5% of all paediatric
solid tumours. It is diagnosed mainly in teenagers and mostly
localised in the long bones of limbs. Anatomopathological analysis
of tumour biopsy confirms only the diagnosis of high-grade
osteosarcoma without any prognostic consequence (Dahlin and
Unni, 1986; Huvos, 1991). In one study, the site of the primary
tumour had no correlation with survival (Nagler et al, 2000),
whereas others have reported a significant trend towards survival
in the axial or appendicular flat bone high-grade osteosarcomas
(Duffaud et al, 2000; Gadwal et al, 2001).
In this study, after diagnosis, the patients were treated with the
OS 94 protocol, which included preoperative chemotherapy,
followed by surgery and postoperative chemotherapy. In this
protocol of the French Society of Paediatric Oncology (SFOP), a
randomised preoperative chemotherapy was administered. The
first line combined either anthracycline and high-dose methotrex-
ate or etoposide, ifosfamide and high-dose methotrexate. After
surgery, patients were classified as good (GR) or poor responders
(PR) to preoperative chemotherapy according to the histological
grading system established by Huvos et al (1977). Postoperatively,
GR were treated with the same drugs and PR received a second-line
chemotherapy. Assessment of histological response to preoperative
chemotherapy is currently the only major prognostic tool. Thus, a
clear need exists for early identification of patients that would
relapse or fail to respond. Until now, the validation of prognostic
diagnostic factors has been unsuccessful.
In the majority of primary osteosarcomas, the aetiology is
unknown, but, for a minority, it occurs in the setting of a previous
cancer, such as a hereditary mutation of retinoblastoma or an
autosomic recessive mutation of p53 in the Li-Fraumeni syndrome
(Huvos et al, 1977; Malkin et al, 1990; Alonso et al, 2001). These two
genes, localised in 13q14 and 17p13, respectively, could therefore be
involved in the multistep oncogenesis model of high-grade
osteosarcomas. Indeed, the currently accepted model of oncogenesis
corresponds to a stepwise accumulation of genomic defects.
Until now, the histological analysis at diagnosis and on surgical
resection has been insufficient in explaining the oncogenesis
of osteosarcomas and the worse evolution of some GR.
Immunohistochemistry has allowed analysis of the expression of
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sseveral protein targets, like proteins involved in cell cycle or
differentiation, but with a low sensitivity (Wadayama et al, 1994;
Ferracini et al, 1995; Nielsen et al, 1998; Maitra et al, 2001; Park
et al, 2001). Likewise, cytogenetic studies of osteosarcomas have
shown various complex cytogenetic changes involving some
chromosomes but without any specific pattern (Mertens et al,
1993; Ozisil et al, 1994). At the molecular level, some of the
biological factors proposed thus far as potential prognostic factors
in osteosarcoma are p15, p16 (Nielsen et al, 1998; Maitra et al,
2001), p53 (Park et al, 2001), Rb (Wadayama et al, 1994) and c-met
(Ferracini et al, 1995; Oda et al, 2000), but these studies have
mainly been performed on small populations.
Allelotyping analyses by identification of microsatellite mod-
ifications could reveal directly at the DNA level the presence of
chromosomal alterations and could characterise either chromo-
somal (allelic imbalance or AI) or microsatellite instabilities
(MSIs). The presence of MSIs identifies the repair error phenotype
(RER) (Karran, 1996). Although the allelotyping is a powerful and
sensitive method, it does not establish whether allelic imbalances
correspond to allelic gains or losses. Microsatellite studies can
however allow the characterisation of some loci potentially
involved in the multistep carcinogenesis, like p16, p53 and Rb
genes. These were the cell cycle genes shown to be most frequently
altered in osteosarcomas in previous studies, but, with contro-
versial prognostic implications (Tsuchiya et al, 2000; Maitra et al,
2001; Park et al, 2001). A French working group has produced a
first retrospective molecular study, showing a significant trend in
the association of alteration at Rb locus and a bad prognosis
(Feugeas et al, 1996). Up to now, the status of many differentiation
and proliferation genes such as c-met or APC, which are known to
be involved in other cancers have not yet been analysed in
paediatric osteosarcomas. Our study, including 54 patients, was
therefore designed to identify prognostic factors assessable at
diagnosis in osteosarcoma by analysing the microsatellite status of
5q21, 7q31, 9p21, 13q14 and 17p13 loci. Furthermore, the results
were correlated with the histological response to preoperative
chemotherapy and survival.
PATIENTS AND METHODS
Patients
In total, 54 patients (Table 1) with primary high-grade osteosarcoma
were included in our molecular study. All were treated following the
guidelines of the OS 94 protocol between November 1994 and
October 2001. Six patients had a metastatic disease at diagnosis
(patients 16, 19, 37, 42, 49 and 53). The population consisted of 30
GR and 23 PR, according to the histopathological grading reported
by Huvos et al (1977). Only one patient was not assessable. The GR
patients were defined with a necrosis cutoff of 95% or more. This
population comprised 30 boys and 24 girls. The median age at
diagnosis was 13 years old (range from 4 to 20 years). The initial
tumour localisation consisted of 31 femurs, 12 tibias, two fibulas, five
humerus, one mandibular and two pelvises. In one case, these data
were not assessable. At the end of our study, among these 54
patients, 42 are in first continuous complete remission (CCR1), two
in second continuous complete remission (CCR2), two in partial
remission, one in relapse and seven died. All deaths were because of
progressive and metastatic osteosarcomas, highly resistant to
chemotherapy. No toxic death was observed in this cohort. The
median survival was 57 months (range from 3 to 86 months).
Sample collection for molecular analysis
Biopsies from 54 patients were collected at diagnosis, fresh–frozen
and stored at  801C. The biopsies were histologically characterised
by a pathologist. In addition, samples from the surgical resection,
following the preoperative chemotherapy, were collected in 13
cases. The histological grading was made in these 13 cases
according to the previously defined necrosis cutoff. For one
patient, we obtained the relapse tissue and for another, the
metastatic specimen. Paired normal tissue was obtained from
peripheral blood samples conserved on Whatman paper.
METHODS
DNA extraction Tissue and blood paired DNA were purified as
described in Miller et al (1988) and Schneider et al (2000). Tumour
and blood genomic DNA concentrations ranged from 50 to
400ngml
 1 and from 1 to 10ngml
 1, respectively.
Microsatellite analysis Six microsatellites were analysed on
paired normal and biopsy DNA. They were informative for p53
(TP53), localised in the Rb gene (RB1, intron 20), in the 9p21
(D9S171) and 7q31 (D7S486) regions and at the 5q21 locus. D5S346
and D5S492 at 5q21 were centromeric and telomeric, respectively,
in a region containing the APC gene among others. Sequences of
primers were obtained from the genomic database (http://
www.ncbi.nlm.nih.gov/genemap99 and http://www.gdb.org).
Genomic DNA from both the paired samples (10ng) was amplified
by PCR in a total volume of 50ml using 1.2U of Taq polymerase
and 4pmol of both forward and Cy5 labelled reverse primers. PCR
was carried out in an Omnigen Hybaid Thermocycler (Hybaid Ltd,
Ashford, UK) using the following protocol: 7min at 951C, 35 cycles
of 1min at 951C, 1min at 551C( D9S171, D5S346, D5S492, TP53)
and 531C( RB1, D7S486) and 1min at 721C, followed by 5min at
721C.
PCR product analysis After electrophoresis on denaturing urea
gel on an ALF (Automated Laser Fluorescent) sequencer
(Amersham-Pharmacia Biotech, Uppsala, Sweden), amplified
fragments were directly detected and quantified by the Alfwin
Fragment Analyser software package. A modification of the allele
ratio in paired tumour and leukocyte DNA is described as AI
(Figure 1). The presence of additional peaks is described as MSI.
This technique is highly reproducible and sensitive. As determined
previously in our laboratory, a cutoff of 20% was used to identify
significant AI (Schneider et al, 2000). Each alteration was
confirmed at least twice by PCR.
Statistics
All data were computed using SPSS 9.0 for windows (SPSS, Inc.
Chicago, IL, USA). The survival function was estimated using
Kaplan–Meier test. The log rank to compare survival and the
w
2 test were used to analyse correlation between the AI and
subgroups of patients.
RESULTS
We obtained paired blood and tumour biopsies at diagnosis from
54 children. In addition for 13 out of 54 cases, we also collected
surgical resection fragments, allowing a comparison between pre-
and postchemotherapy. Characteristics and survival of the entire
group are detailed in Table 1. Overall, the event-free survival (EFS)
rate at 5 years was 80%. Histological diagnosis showed, in all cases,
high-grade osteosarcomas. In all, 30 GR and 23 PR were identified.
All the surgical resections were histologically reviewed and all PR
patients had less than 95% tumour necrosis. The statistical analysis
of these two groups revealed a significant difference of EFS at 5
years (92 and 69%, respectively, P¼0.01) (Figure 2), associating
PR with a worse prognosis. Microsatellite analysis was realised on
all samples using six couples of primers. Primer sets were
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sinformative for the p53 gene, localised in Rb or in 9p21, 5q21 and
7q31 regions. The last three loci contain, in addition to genes of
unknown functions in oncogenesis, genes involved in cell cycle
and differentiation, like p16, APC and c-met.
Frequent AI are observed in biopsies as compared to
blood DNA
The allelotyping did not detect additional peaks (MSI) in our
population for our set of six microsatellites. Furthermore, no MSIs
were detected at 10 additional microsatellites analysed (D3S700,
D3S1283, D4S3019, D4S428, D7S2455, D7S2595, D17S800,
D17S1818, D20S107 and D20S855). Thus, it appears that repair
error mechanisms were probably not involved in these tumours. In
heterozygous patients, a change in the ratio between the two
amplified alleles was frequently observed when blood and paired
tumour biopsies were compared, indicating the presence of AI. In
all, 94% (51 out of 54) of the patients showed at least one AI,
demonstrating that our selection of six microsatellites was highly
informative for identifying rearranged primary osteosarcomas at
Table 1 Clinical and molecular data of the 54 patients included in our study that are in CCR1 or CCR2, in relapse, in partial remission (PR) or dead
Patients
Age
(years) Localisation
Histologic
response
Survival
(months) TP53 D7S486 RB1 D9S171 D5S346 D5S492 Status
1 7 Femur GR 76 h h AI AI h h CCR1
2 14 Tibia GR 81 h h N AI N h CCR1
3 16 Tibia PR 81 h AI h h h h CCR1
4 10 Femur GR 77 AI N AI h N h CCR1
5 13 Tibia GR 82 AI AI AI h AI AI CCR1
6 12 Femur PR 83 h N AI AI AI h CCR1
7 15 Pelvis PR 78 AI AI AI AI AI h CCR1
8 13 Femur PR 86 AI N AI h N h CCR1
9 12 Femur GR 73 AI N N AI AI h CCR1
10 13 Humerus GR 85 AI AI AI N AI h CCR1
11 13 Tibia GR 74 AI AI AI h h h CCR1
12 11 Femur GR 86 AI N N N N h CCR1
13 14 Femur PR 86 N N AI N AI h CCR1
14 13 Femur GR 80 AI h N AI h h CCR1
15 8 Femur GR 74 AI AI AI N N h CCR1
16
a 15 Tibia PR 65 AI h N AI N h Dead
17 15 Pelvis GR 71 h h h AI AI h CCR1
18 Unknown Unknown GR 72 N N N N N N CCR1
19
a 8 Humerus Unknown 57 h h AI N AI h CCR1
20 17 Femur PR 22 h h N AI AI AI CCR2
21 9 Femur GR 35 h h h h AI AI CCR2
22 4 Tibia GR 54 h N AI h N h CCR1
23 17 Femur PR 57 AI h AI N N h CCR1
24 16 Humerus PR 71 AI h AI N AI h Dead
25 12 Tibia PR 65 N h N N N h Dead
26 9 Femur GR 78 N N h AI AI AI CCR1
27 12 Femur PR 69 AI N N h N N CCR1
28 13 Femur GR 39 AI N AI AI N h CCR1
29 13 Femur GR 19 AI AI AI h N h Dead
30 10 Femur PR 39 h h AI AI AI h CCR1
31 12 Femur GR 28 h N AI h AI h CCR1
32 9 Tibia GR 75 AI N AI h N h CCR1
33 14 Femur GR 32 AI h h AI AI h CCR1
34 17 Fibula GR 32 AI h h AI AI AI CCR1
35 20 Humerus GR 52 h h h h AI h CCR1
36 13 Fibula GR 77 N h h h N N CCR1
37
a 15 Femur PR 19 AI h AI N AI h Dead
38 7 Femur GR 54 AI h AI AI h N CCR1
39 15 Tibia PR 69 AI N h h h h CCR1
40 10 Humerus GR 77 AI AI h h AI h CCR1
41 15 Femur PR 11 h h N AI h h Relapse
42
a 9 Femur PR 7 h AI h AI AI AI PR
43 13 Tibia GR 28 AI N AI AI h N CCR1
44 9 Mandibular PR 7 N N AI AI AI h Dead
45 7 Femur GR 30 AI h h h h N CCR1
46 14 Femur GR 30 h h AI AI h h CCR1
47 13 Femur PR 12 AI N h N h h CCR1
48 12 Femur PR 54 h N AI AI h h CCR1
49
a 14 Tibia PR 32 AI N h h AI AI CCR1
50 13 Femur GR 38 h h N AI N N CCR1
51 16 Femur PR 24 h N AI h AI h CCR1
52 16 Tibia PR 24 h AI h N AI h PR
53
a 15 Femur GR 3 AI N AI h AI AI CCR1
54 10 Femur PR 12 AI AI h AI AI h Dead
29 AI
=83%
11 AI
=34%
27 AI
=71%
23 AI
=66%
26 AI
=58%
h Dead
aThe results concerned homozygous (h) or heterozygous patients (with AI or normal status (N)).
aMetastatic patients. (GR=good responders (30); PR=poor responders (23).
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sdiagnosis (Table 1). Samples (three out of 54), lacking micro-
satellite alterations (patients 18, 25 and 36), showed, in fact, AI at
two other microsatellites targeting 3p (D3S1293 and D3S3700),
thus confirming the presence of tumour cells. In the informative
tumours, we observed a variation of the intensity of the allelic ratio
ranging from 35 to 90% in comparison to normal DNA. This was
consistently higher than the previously defined cutoff. These
percentages confirmed the high proportion of tumour cells in our
biopsies. In each biopsy, the observed allele ratio was at the same
intensity for every loci analysed.
A high level of AI frequency was observed at each locus, except
for the microsatellite targeting 7q31. Taking into account
heterozygous loci, AI was found in 83% (29 out of 35) for TP53,
71% (27 out of 38) for RB1, 66% (23 out of 35) for D9S171, 34% (11
out of 32) for D7S486 and 58% (26 out of 45) for D5S346 and
D5S492 (Table 1). Furthermore, a slightly higher proportion of
homozygous loci, than reported in the database, was observed at
D7S486 (41 vs 35% for TP53, 30% for RB1, 35% for D9S171 and
17% for 5q21). At least one of the cell cycle genes, p53, Rb or locus
9p21, was altered in 88% biopsies. In order to analyse the data at
the locus containing APC, we used two microsatellites flanking this
region (D5S346 and D5S492), and considered this locus as
informative if it was heterozygous for both markers or if at least
one of the two markers was modified, and the second one
noninformative. In cases where both microsatellites (D5S346 and
D5S492) were informative, results at both sites were always
identical, either both AI or both normal. In GR and PR subgroups,
AI frequencies for each microsatellite did not show statistical
differences (Figure 3). In the subgroup, combining relapses, partial
responses to treatment or dead patients (patients 16, 24, 25, 29, 37,
41, 42, 44, 52 and 54), a higher AI frequency was observed at
D7S486 and at D5S3546 and D5S492, but a statistical significance
was found only for the 7q31 locus (P¼0.04) (Figure 3).
Event-free survival was investigated for each microsatellite in
the entire population. No significant differences in survival time
were observed to be related to the presence of AI at TP53, RB1 or
D9S171. Interestingly, a normal status at 7q31 was associated with
a significantly better EFS not only in the whole population, but also
in the PR subgroup (Figure 4) (P¼0.03). The association of a
rearrangement at markers flanking 5q21 with a bad prognosis is
suggested by the curves, but the correlation is not statistically
significant (P¼0.15) (Figure 5).
Comparison of tumour samples at diagnosis with the
surgical resection following chemotherapy
Fortunately, we were able to collect a surgical sample in addition to
biopsy for 13 cases (nine PR and five GR) (Table 2). In three out of
five GR, the presence of AI was still observed (patients 4, 10 and
29). All five GR patients had between 95 and 99% necrosis.
However, the allotyping analysis allowed us to identify four
different groups.
First, four children (patients 1, 3, 11, 49), comprising two GR
and two PR, normalised their surgical resection, probably
suggesting the absence of any significant tumour cell population
according to our molecular detection. These four patients are alive
and in CCR1. In the second group (one PR and one GR, cases 6 and
10), the alterations at 7q31 and 5q21 regions persisted, but the
other AI previously identified were no longer observed. The third
group concerned four patients (cases 4, 8, 27, 54), who showed the
same rearrangements in both biopsy and tumour resection. For
these four patients, our molecular analyses suggested an initial
significant chemoresistance of the localised tumour cell popula-
tion, even though one patient was classified as GR in CCR1.
Finally, in the last group (patients 16, 29, 47), new microsatellite
alterations appeared in comparison with biopsy, which were
localised at the locus 5q21 for patient 16 (PR) and 29 (GR). Both
Blood
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Figure 1 Allelic imbalance (AI). Genomic DNA was extracted from
blood, tumour biopsy at diagnosis and tumour of surgical resection (patient
1). PCR of D9S171 was separated by using a sequencing analyser (ALF
Pharmacia). The microsatellite was informative and shows a change in the
ratio between the two amplified alleles comparing blood and paired
tumour biopsies (black arrow). This patient normalised his surgical tumour
sample, there is no change in the ratio between the two amplified alleles
comparing blood and paired surgical tumour.
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Figure 2 Kaplan–Meier EFS curves for the GR (-----) and PR (——)
with a statistical significance (P¼0.01).
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Figure 3 Allelic imbalance (AI) frequencies and percentages of normal
(N) status at the five targeted loci in the different subgroups of patients:
GR, PR and the population combining different events such as partial
remission, relapse and deaths (event).
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spatients died. Histological response was not correlated to the
results of microsatellite analysis in any of the groups. In the
relapsing and metastatic specimens, we detected the same
alterations, as observed in biopsy or surgical samples, suggesting
the evolution of the same tumour clone (Table 2).
DISCUSSION
Overall considerations about our biopsy collection
This study was designed to identify molecular prognostic factors
assessable at diagnosis, as Rb and p53 genes, 9p21 and 7q31 loci
and a region surrounding the APC gene. Candidate genes in 9p21
and 7q31 are p16 and c-met, respectively. Altogether, clinical and
statistical data of our population appeared to be representative of
the usual histological diagnoses and treatment responses in the
multicentre OS 94 protocol. The main difficulty was obtaining
paired blood and tumour DNA samples, mainly because of the low
incidence of such sarcomas. Despite this problem, our study
included 54 primary paediatric high-grade osteosarcomas, treated
with the same therapeutic protocol. Previous published studies
concerned either adult or paediatric populations, mixed the low-
or high-grade osteosarcomas and had different therapeutic regi-
mens (Ozisil et al, 1994; Patino-Garcia and Sierrasesumaga, 1997;
Nielsen et al, 1998; Tsuchiya et al, 2000). To our knowledge, no
other molecular study has investigated such a large homogeneous
paediatric population.
Our microsatellite analysis was achieved in 54 paired blood and
fresh–frozen biopsy specimens. Allelic imbalances were detected,
but there were no MSI, allowing us to infer that the RER phenotype
(Fearon and Vogelstein, 1990; Kinzler and Vogelstein, 1996;
Hanahan and Weinberg, 2000) is not the main mechanism
involved in the oncogenesis of osteosarcoma. Belchis et al (1996)
showed MSI at the retinoblastoma locus in eight out of 18
informative osteosarcomas, but their study investigated formalin-
fixed, paraffin-embedded samples, which could affect microsatel-
lite analyses. With this panel of six microsatellites, 94% of our
population showed DNA alterations at diagnosis. This high
frequency recommends the choice of this sensitive and powerful
method and these selected markers for routine analyses at
diagnosis. Furthermore, our results showed a high intensity of
allelic ratio alterations, confirming the high percentages of tumour
cells in these biopsies. The clonal homogeneity of tumour samples
was confirmed by the same high percentage allelic ratio intensity at
each locus analysed from the same tumour.
Analysis of results and comparison of biopsy DNA samples
and paired blood DNA for the loci involved in the cell cycle
With this sensitive technique, high AI frequencies in p53, Rb and
9p21 loci were observed. These high frequencies of alterations at
TP53 and 9p21 (locus containing CDK inhibitor INKAp16) were in
agreement with previous data (Nielsen et al, 1998; Tsuchiya et al,
2000; Benassi et al, 2001). Several studies concerning these genes
have reported lower frequencies, however they used either protein
level analysis or mutation detection and are therefore difficult to
compare with microsatellite analysis. In contrast with these
studies, we did not find any correlation between the presence of
AI and prognosis (Nielsen et al, 1998; Maitra et al, 2001).
Concerning the Rb locus, the same frequency (70%) of AI was
found as in the previous SFOP study (Feugeas et al, 1996).
According to the previous report, there was no significant
correlation between the abnormalities at this locus and the
histological grading in our present study (Feugeas et al, 1996).
In contrast, in our study no correlation between EFS and AI at RB1
was observed, while the previous study suggested correlation of Rb
locus alteration and poor prognosis. Probably, such discrepancy
could be explained by the modifications of the chemotherapy
between these two protocols. In fact, we analysed a different
prognostic group of patients, since in our study 30 GR and 23 PR
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Figure 4 Kaplan–Meier EFS curves of the microsatellite analysis at 7q31
locus for the entire population (A) and for the PR (B) with a statistically
significant association between the presence of AI and a worse prognosis
(——).
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Figure 5 Kaplan–Meier EFS curve for the PR with AI at 5q21 region and
without alterations. This statistical analysis showed a trend between the
presence of AI and a worse survival.
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et al, 1996).
Altogether, our results, like previous data, confirmed the
putative role of 9p21 region and Rb/p53 signalling pathway in
osteosarcomas (Nielsen et al, 1998; Tsuchiya et al, 2000; Benassi
et al, 2001). However, the lack of correlation between survival and
the presence of alteration at those loci suggested that other
mechanisms are involved in the sensitivity to chemotherapy.
Microsatellite analysis of 5q21 and 7q31: a prognostic
marker and a new probable target diagnosis
Results at the locus 7q31 and at the region containing APC
suggested a striking and interesting role for these sites in
osteosarcoma oncogenesis, even though the frequencies of
rearrangements at the locus 7q31 were rather low (34%)
(Table 1). Nevertheless, when we only considered the group
comprising partial remissions, relapses and patients who died, this
AI frequency reached 80%, resulting in a significant correlation
with this bad prognostic subgroup (P¼0.04). Thus, our data have
identified a new region involved in the prognosis of osteosarco-
mas. The significant correlation between alteration of 7q31 and a
worse prognosis demonstrates its prognostic role. Results obtained
at this locus were in agreement with previous c-met studies,
concluding that c-met could play a role in aggressive osteosarco-
mas (Ferracini et al, 1995; Oda et al, 2000). Even though such
results should be confirmed in a larger population with a longer
follow-up and a c-met gene quantitative analysis, the knowledge of
the presence of AI at this locus could be useful in predicting GRs
that will relapse and might encourage the use of kinase inhibitors
in osteosarcomas treatments in future.
At the locus 5q21, the use of two microsatellites, surrounding
the APC gene, increased the specificity of allelotyping at this site
and allowed us to speculate that the high percentage of
rearrangement could strengthen the fundamental role of this gene
in osteosarcoma. To our knowledge, such results in osteosarcomas
have only been described in one recent study (Monaghan et al,
2001), since APC has previously been known to play a role in the
oncogenesis of colorectal cancer (Polakis, 1997). Furthermore,
statistical analyses showed a slight trend for the presence of AI at
5q21 correlating with the poor response to chemotherapy, in
agreement with a trend towards a worse prognosis in case of AI at
5q21. However, a larger cohort would be required to confirm this.
In addition, further studies would be necessary to define precisely
the status of this gene or the presence of mutation.
Allelotyping surgical resection specimens as additional
tool for refining the histological response to preoperative
chemotherapy
Since some GR are known to relapse earlier, refining the
stratification of GR could help to adjust treatment. Our allelotyp-
ing of surgical resections was very informative, allowing us to
characterise four subgroups that did not appear to be correlated
with histological response. In the groups where AI were still
detected in the surgical specimens, we identified two situation:
either same alterations or new AI were observed in surgical
samples compared to biopsies. The second situation suggested the
presence of new cellular clones, possibly selected by chemotherapy
since the reproducibility and high intensity of AI agreed strongly
with the presence of a dominant cell clone at diagnosis. It should
be noted that the patients who died (patients 16 and 29) had
additional AI at 5q21, strengthening the role of this loci in poor
prognosis contrary to the case in colorectal cancer (Polakis, 1997).
In fact, only GR with persisting AI should be carefully followed
since these GR could belong to the subgroup who could relapse
earlier. Altogether, allelotyping at surgical resection time could
complete the histological analysis and help to provide a more
precise stratification of each subgroup of responders.
In conclusion, our large population of 54 paediatric osteosarco-
mas was investigated with five targeted loci. These five loci
Table 2 Molecular analysis of the 13 patients whose normal tissue, biopsy at diagnosis and surgical resection samples were analysed
TP53 D7S486 RB1 D9S171 D5S346 D5S492 Status
Patient 1 GR Biopsy h h AI AI h h CCR1
Tumour h h N N h h
Patient 3 PR Biopsy h AI h h h h CCR1
Tumour h N h h h h
Patient 4 GR Biopsy AI N AI h N h CCR1
Tumour AI N AI h N h
Patient 6 PR Biopsy h N AI AI AI h CCR1
Tumour h N N N AI h
Patient 8 PR Biopsy AI N AI h N h CCR1
Tumour AI N AI h N h
Metastasis AI N AI h N h
Patient 10 GR Biopsy AI AI AI N AI h CCR1
Tumour N AI N N AI h
Patient 11 GR Biopsy AI AI AI h h h CCR1
Tumour N N N h h h
Patient 16 PR Biopsy AI h N AI N h Dead
Tumour AI h N AI AI h
Patient 27 PR Biopsy AI N N h N N CCR1
Tumour AI N N h N N
Patient 29 GR Biopsy AI AI AI AI N h Dead
Tumour AI AI AI AI AI h
Patient 47 PR Biopsy AI AI h N h h CCR1
Tumour AI AI h AI h h
Patient 49 PR Biopsy AI N h h AI AI CCR1
Tumour N N h h N AI
Patient 54 PR Biopsy AI AI h AI AI h Dead
Tumour AI AI h AI AI h
Relapse AI AI h AI AI h
The results were homozygous status (h), AI or normal status (N). This study involved GR and PR that were in first CCR1 or dead.
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and revealed a potential implication of 5q21 region containing
APC. A significant correlation between presence of rearrangements
at 7q31 and a worse prognosis was observed. Finally, the use of
targeted microsatellite analysis at surgical resection could be an
additional tool to make more precise stratification, especially in GR.
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